Applications of Pharmacogenetics in Pharmaceutical Research and Development

John F. Morrow, [1] Recombinant DNA techniques Methods in Enzymology. ,vol. 68, pp. 3- 24 ,(1979) , 10.1016/0076-6879(79)68003-5

Richard M.J. Bohmer, Clayton M. Christensen, John Kenagy, Will disruptive innovations cure health care Harvard Business Review. ,vol. 78, pp. 102- 199 ,(2000)

TE Klein, RB Altman, Niclas Eriksson, BF Gage, SE Kimmel, MT Lee, NA Limdi, D Page, DM Roden, MJ Wagner, MD Caldwell, JA Johnson, YT Chen, MS Wen, Y Caraco, I Achache, S Blotnick, M Muszkat, JG Shin, HS Kim, G Suarez-Kurtz, JA Perini, E Silva-Assuncao, JL Anderson, BD Horne, JF Carlquist, RL Berg, JK Burmester, BC Goh, SC Lee, F Kamali, E Sconce, AK Daly, AH Wu, TY Langaee, H Feng, L Cavallari, K Momary, M Pirmohamed, A Jorgensen, CH Toh, P Williamson, H McLeod, JP Evans, KE Weck, C Brensinger, Y Nakamura, T Mushiroda, D Veenstra, L Meckley, MJ Rieder, AE Rettie, M Wadelius, H Melhus, CM Stein, U Schwartz, D Kurnik, E Deych, P Lenzini, C Eby, LY Chen, P Deloukas, A Motsinger-Reif, H Sagreiya, BS Srinivasan, E Lantz, T Chang, M Ritchie, LS Lu, Estimation of the warfarin dose with clinical and pharmacogenetic data The New England Journal of Medicine. ,vol. 360, pp. 753- 764 ,(2009) , 10.1056/NEJMOA0809329

Allen D. Roses, Pharmacogenetics and the practice of medicine. Nature. ,vol. 405, pp. 857- 865 ,(2000) , 10.1038/35015728

J. Kaiser, DNA sequencing. A plan to capture human diversity in 1000 genomes. Science. ,vol. 319, pp. 395- 395 ,(2008) , 10.1126/SCIENCE.319.5862.395

A. L. McGuire, M. K. Cho, S. E. McGuire, T. Caulfield, The Future of Personal Genomics Science. ,vol. 317, pp. 1687- 1687 ,(2007) , 10.1126/SCIENCE.1147475

Ismail Kola, John Landis, Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. ,vol. 3, pp. 711- 716 ,(2004) , 10.1038/NRD1470

Magnus Ingelman-Sundberg, Pharmacogenomic Biomarkers for Prediction of Severe Adverse Drug Reactions The New England Journal of Medicine. ,vol. 358, pp. 637- 639 ,(2008) , 10.1056/NEJME0708842

Arthur L. Holden, The innovative use of a large-scale industry biomedical consortium to research the genetic basis of drug induced serious adverse events Drug Discovery Today: Technologies. ,vol. 4, pp. 75- 87 ,(2007) , 10.1016/J.DDTEC.2007.11.003

Allen D. Roses, Daniel K. Burns, Stephanie Chissoe, Lefkos Middleton, Pamela St. Jean, Disease-specific target selection: a critical first step down the right road. Drug Discovery Today. ,vol. 10, pp. 177- 189 ,(2005) , 10.1016/S1359-6446(04)03321-5